Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Introduction: Patients with Diffused large B cell lymphoma (DLBCL) who are also co-infected with Hepatitis B virus (HBV) may experience HBV reactivation during immunochemotherapy which can delay or prematurely terminate anti-tumor treatment. It is usually considered that patients who are hepatitis B surface antigen-positive (HBsAg+) have a higher rate of HBV reactivation and a poorer prognosis compared with patients who have resolved hepatitis B virus infection (HBsAg+/anti-HBc+).
Introduction: Extranodal nature killer/T cell lymphoma (NKTCL) accounts for about 6% of all kinds of lymphoma. Asparaginase based chemotherapy regime greatly improved the outcome of NKTCL. However, asparaginase resistance still exists and patients who failed first line asparaginase treatment appeared a poor prognosis. At present, the mechanism of asparaginase resistance in NKTCL was few elucidated.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
